MannKind Investor Relations Material
Latest events
Q4 2023
MannKind
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from MannKind Corporation
Access all reports
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza (insulin human), a small molecule inhalation powder that delivers rapid insulin absorption directly into the bloodstream. Its product portfolio also includes Technosphere dry powder inhalation system and pulmonary delivery devices.
Key slides for MannKind Corporation
Q4 2023
MannKind Corporation
Q4 2023
MannKind Corporation
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States